a:5:{s:8:"template";s:12592:"<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="utf-8"/>
<title>{{ keyword }}</title>
<meta content="text/html; charset=utf-8" http-equiv="Content-Type"/>
<meta content="width=device-width,initial-scale=1.0" name="viewport"/>
<link href="http://fonts.googleapis.com/css?family=Yanone+Kaffeesatz:400,700" rel="stylesheet" type="text/css"/>
<link href="http://fonts.googleapis.com/css?family=Oswald" rel="stylesheet" type="text/css"/>
<style rel="stylesheet" type="text/css">@charset "utf-8";body,div,footer,form,h1,h2,h3,header,html,img,li,nav,p,span,time,ul{margin:0;padding:0;border:0;outline:0;font-size:100%;vertical-align:baseline;background:0 0}body{line-height:1}footer,header,nav{display:block}nav ul{list-style:none}a{margin:0;padding:0;font-size:100%;vertical-align:baseline;background:0 0}a{margin:0;padding:0;font-size:100%;vertical-align:baseline;background:0 0}input{vertical-align:middle}#sb-site,.sb-slidebar,body,html{margin:0;padding:0;-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}body,html{width:100%;overflow-x:hidden}html{height:100%}body{min-height:100%;height:auto;position:relative}#sb-site{width:100%;position:relative;z-index:1}.sb-slidebar{height:100%;overflow-y:auto;position:fixed;top:0;z-index:0;display:none;background-color:#fff;-webkit-transform:translate(0)}.sb-right{right:0}.sb-slidebar{width:30%}@media (max-width:480px){.sb-slidebar{width:70%}}@media (min-width:481px){.sb-slidebar{width:55%}}@media (min-width:768px){.sb-slidebar{width:40%}}@media (min-width:992px){.sb-slidebar{width:30%}}@media (min-width:1200px){.sb-slidebar{width:20%}}#sb-site,.sb-slidebar{-webkit-transition:-webkit-transform .4s ease;-moz-transition:-moz-transform .4s ease;-o-transition:-o-transform .4s ease;transition:transform .4s ease;-webkit-transition-property:-webkit-transform,left,right;-webkit-backface-visibility:hidden} @font-face{font-family:'Yanone Kaffeesatz';font-style:normal;font-weight:700;src:url(http://fonts.gstatic.com/s/yanonekaffeesatz/v14/3y9I6aknfjLm_3lMKjiMgmUUYBs04aUXNxt9gW2LIftoEdKZd2GP.ttf) format('truetype')}body{margin:0;font-family:'Century Gothic',Helvetica,Arial,Sans-serif;font-size:14px;line-height:20px;text-align:left;vertical-align:top;background:#fff;color:#000}body,form,h1,h2,h3,p{margin:0;padding:0}h1{font-size:24px;padding:0 0 10px 0}a:link,a:visited{text-decoration:none;color:#ef717d}a:hover{color:#f28b2e}p{padding:0 0 10px}.clear{clear:both}#sb-site{}#wrapper{background:#fff;margin:0 auto 0 auto;max-width:1000px;text-align:left;width:100%}#innerWrap{padding:0 30px;width:auto}#mainHd{min-height:163px;width:100%}#mainHd h1{float:left;height:163px;margin:0;text-indent:-9999px;width:234px}#mainHd h1 a{display:block;height:163px;width:234px}#mainHd .menu{border-top:6px double #999b9a;border-bottom:6px double #999b9a;float:right;font-family:'Yanone Kaffeesatz';font-size:44px;font-weight:700;line-height:44px;list-style:none;margin:25px 0 10px;padding:5px 0;max-width:706px;text-transform:uppercase;width:auto}#mainHd .menu li{float:left;list-style:none;position:relative}#mainHd .menu li a{padding:0 12px}#mainHd .menu li ul{display:none;position:absolute;top:44px;left:0;width:180px;background:#fff;box-shadow:0 0 4px #606060;z-index:99}#mainHd .menu li:hover ul{display:block}#mainHd .menu li ul li{float:none;font-size:24px;line-height:24px;margin:0;padding:0}#mainHd .menu li ul li a{display:block;padding:10px 0 10px 15px}#mainHd .menu li:nth-child(6n-5) a{color:#ef7163}#mainHd .menu li:nth-child(6n-5) a:hover{color:#999b9a}#mainHd .menu li:nth-child(6n-4) a,#mainHd .menu li:nth-child(6n-4) ul li a{color:#ef717d}#mainHd .menu li:nth-child(6n-4) a:hover,#mainHd .menu li:nth-child(6n-4) ul li a:hover{color:#999b9a}#mainHd .menu li:nth-child(6n-3) a{color:#f49081}#mainHd .menu li:nth-child(6n-3) a:hover{color:#999b9a}#mainHd .menu li:nth-child(6n-2) a{color:#f28b2e}#mainHd .menu li:nth-child(6n-2) a:hover{color:#999b9a}#mainHd .menu li:nth-child(6n-1) a{color:#fac829}#mainHd .menu li:nth-child(6n-1) a:hover{color:#999b9a}  .menu{border-top:1px solid #ccc;clear:both;font-family:'Yanone Kaffeesatz';font-size:30px;font-weight:700;line-height:30px;list-style:none;padding-top:5px;text-align:right;text-transform:uppercase}.sb-slidebar .menu li{border-bottom:1px solid #ccc;padding:0 0 5px;margin-bottom:5px}.sb-slidebar .menu ul{list-style:none;padding-top:5px}.sb-slidebar .menu ul li{border-bottom:none;font-size:24px;line-height:24px;padding:0 0 0;font-weight:400}.sb-slidebar .menu ul li a{color:#7bd3c7}.sb-slidebar .menu ul li a:hover{color:#5fbbb6}.sb-toggle-right{display:none;cursor:pointer;float:right;margin:0;padding-top:30px;width:25px}.sb-toggle-right .navicon-line{background:#ef717d;display:block;height:5px;margin:0 auto 5px;width:25px}.sb-toggle-right:hover .navicon-line{background:#5fbbb6}#mainFoot{background:#f49081;box-sizing:border-box;clear:both;color:#fff;padding:30px 2% 0 2%;width:100%}#leftFt{box-sizing:border-box;float:left;max-width:470px;padding-right:15px;width:50%}#leftFt #ftNav .menu{color:#fff;list-style:none;float:left;border-top:6px double #fff;border-bottom:6px double #fff;font-family:'Yanone Kaffeesatz';font-size:22px;font-weight:700;line-height:22px;padding:5px 0;margin-bottom:15px;text-transform:uppercase;width:100%}#leftFt #ftNav .menu li{float:left;padding:2px 5px 2px 0;border-right:3px solid #fff;margin-right:5px}#leftFt #ftNav .menu li:last-child{padding-right:0;border-right:none;margin-right:0}#leftFt #ftNav .menu li a{color:#fff}#leftFt #ftNav .menu li a:hover{color:#f8d4cf}#leftFt .socialIcons{color:#f8d4cf;font-family:'Yanone Kaffeesatz';font-size:28px;font-weight:700;line-height:28px;list-style:none;float:left;height:33px;text-transform:uppercase;vertical-align:bottom;width:410px}#leftFt .socialIcons::before{content:"DON'T BE ANTI-SOCIAL:"}#leftFt .socialIcons li a{background-position:center bottom;background-repeat:no-repeat;display:block;height:32px;width:32px}#leftFt .socialIcons li a:hover{background-position:center top}#rightFt{box-sizing:border-box;float:right;max-width:470px;padding-left:15px;width:50%}#rightFt::after{clear:both}#rightFt #bioPic{box-sizing:border-box;float:right;height:169px;margin:0 0 10px 15px;padding:5px;width:147px}#rightFt #bioPic img{height:auto;max-width:100%}#rightFt h3{color:#fff;font-family:havana;font-size:57px;font-weight:400;line-height:57px}#rightFt h3 span{color:#fac829}#mainFoot p{line-height:18px}p.copy{clear:both;color:#fff;font-size:10px;line-height:12px;margin:0;padding:10px 0 0}.copy a{color:#606060}.copy a:hover{color:#fff}#slider{margin-bottom:30px}#recBlog{background:#f7f5ef box-sizing:border-box;padding:20px 20px 40px;margin-bottom:20px;float:right;min-height:272px;width:74%}#recBlog h2{color:#ef717d;font-family:'Yanone Kaffeesatz';font-size:34px;font-weight:700;line-height:34px;margin:0 0 5px;padding:0;text-transform:uppercase;width:100%}#recBlog p.date{font-size:12px;line-height:16px}#recBlog .more{color:#fff;float:right;font-family:'Yanone Kaffeesatz';font-size:26px;font-weight:700;line-height:26px;text-transform:uppercase}#recBlog .more a{background:#ef717d;color:#fff;display:block;padding:5px 10px;width:auto}#recBlog .more a:hover{background:#f28b2e}#newsletter{background:#ef717d;box-sizing:border-box;color:#fff;float:left;margin-bottom:20px;padding:20px 20px 50px;width:24%}#newsletter h2{font-family:havana;font-size:48px;font-weight:400;line-height:48px;margin:0;padding:0}#newsletter h3{font-family:'Yanone Kaffeesatz';font-size:24px;line-height:24px;margin:0 0 15px;text-align:right;text-transform:uppercase}#newsletter input[type=email],#newsletter input[type=text]{background:#f799a2;border:none;box-sizing:border-box;height:32px;margin-bottom:10px;padding:5px 10px;width:100%}#newsletter input[type=submit]{background:#fac829;border:none;color:#fff;font-family:'Yanone Kaffeesatz';font-size:26px;font-weight:700;float:right;letter-spacing:normal;line-height:26px;padding:5px 10px;text-transform:uppercase;width:auto}#newsletter input[type=submit]:hover{background:#b1e2dc}#pco,#shco{box-sizing:border-box;float:left;padding-bottom:40px;width:50%}#pco{padding-right:10px}#pco h3{border-top:6px double #999b9a;border-bottom:6px double #999b9a;color:#f28b2e;font-family:'Yanone Kaffeesatz';font-family:havana;font-size:44px;font-weight:400;line-height:44px;margin:0 0 15px;padding:5px 0;text-align:center;width:100%}#shco{padding-left:10px}#shco h3{border-top:6px double #999b9a;border-bottom:6px double #999b9a;color:#5fbbb6;font-family:havana;font-size:44px;font-weight:400;line-height:44px;margin:0 0 15px;padding:5px 0;text-align:center;width:100%}.releaseBlock{box-sizing:border-box;max-width:320px;float:left;height:auto;margin:0;padding:10px;width:50%}.releaseBlock img{height:auto;max-width:100%}input[type=email]{background:#d8d8d8;border:none;box-sizing:border-box;height:40px;margin:0 0 15px;padding:10px 15px;width:100%}::-webkit-input-placeholder{color:#fff}:-moz-placeholder{color:#fff}::-moz-placeholder{color:#fff}:-ms-input-placeholder{color:#fff}.rslides{box-sizing:border-box;position:relative;list-style:none;width:100%;padding:0;margin:0;z-index:0}.rslides li{-webkit-backface-visibility:hidden;position:absolute;display:none;width:100%;left:0;top:0;z-index:0}.rslides li:first-child{position:relative;display:block;float:left}.rslides img{display:block;height:auto;float:left;width:100%;border:0}@media screen and (max-width:960px){#sb-site{background:#fff}#wrapper{padding:0;width:100%}#innerWrap{padding:0 5%;width:90%}#mainHd .menu{font-size:30px;line-height:30px}}@media screen and (max-width:865px){#mainHd{margin-bottom:20px}#mainHd h1{float:none;margin:0 auto}#mainHd .menu{float:left;font-size:44px;line-height:44px;margin:10px auto;max-width:100%;width:100%}#mainHd .menu li:last-child::after{clear:both}#mainHd .socialIcons{padding:0}}@media screen and (max-width:768px){#mainHd h1{float:left;margin:0}#mainHd #searchform,#mainHd .menu,#mainHd .socialIcons{display:none}.sb-toggle-right{display:block}#leftFt .socialIcons{display:none}#leftFt,#rightFt{float:none;margin:0 auto 20px;width:100%;max-width:100%}#newsletter,#recBlog{width:48%}#pco h3,#shco h3{font-size:30px;line-height:30px}.releaseBlock{float:none;margin:0 auto;width:100%}}@media screen and (max-width:480px){#newsletter,#recBlog{float:none;width:100%}#pco,#shco{float:none;padding:0 0 30px;width:100%}}@media only screen and (-webkit-min-device-pixel-ratio:2),only screen and (min--moz-device-pixel-ratio:2),only screen and (-o-min-device-pixel-ratio:2/1),only screen and (min-device-pixel-ratio:2){#mainHd h1{-webkit-background-size:234px 163px;-moz-background-size:234px 163px;-o-background-size:234px 163px;background-size:234px 163px} @font-face{font-family:Oswald;font-style:normal;font-weight:400;src:url(http://fonts.gstatic.com/s/oswald/v31/TK3_WkUHHAIjg75cFRf3bXL8LICs1_FvsUZiYA.ttf) format('truetype')}}</style>
</head>
<body>
<div id="sb-site">
<div id="wrapper">
<div id="innerWrap">
<header id="mainHd">
<h1>{{ keyword }}</h1>
<ul class="menu" id="menu-main-navigation-menu">
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-home menu-item-1995" id="menu-item-1995"><a href="#">{{ keyword }}</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page current_page_parent menu-item-1994" id="menu-item-1994"><a href="#">Blog</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1998" id="menu-item-1998"><a href="#">About</a></li>
<li class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-1999" id="menu-item-1999"><a href="#">Tutorials</a></li>
</ul>
<div class="clear"></div>
</header>
{{ text }}
<p>.</p>
{{ links }}
</div>
<footer id="mainFoot">
<div id="leftFt">
<nav id="ftNav">
<ul class="menu" id="menu-footer-navigation-menu">
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2025" id="menu-item-2025"><a href="#">Terms of Use</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2015" id="menu-item-2015"><a href="#">Contact</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2027" id="menu-item-2027"><a href="#">Info</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2014" id="menu-item-2014"><a href="#">Additional Services</a></li>
</ul> </nav>
<div class="clear"></div>
<p class="copy">{{ keyword }}</p>
</div>
<div id="rightFt">
<div id="bioPic"></div>
<h3>{{ keyword }}</h3>
</div>
<div class="clear"></div>
</footer>
</div>
</div>
</body>
</html>";s:4:"text";s:10442:"<br>138 patent families. <br> <br>Cellectis
 Cellectis' gene edited CAR T-cells: how does it work? Contract manufacturing from Lonza will complement Cellectis' in-house manufacturing at its two sites that are currently under construction. Free newsletter Cellectis is a clinical-stage biopharmaceutical company developing the Next-Generation CAR T-Cells to Cure Cancer. The United States Food and Drug Administration (FDA) has granted investigational new drug (IND) for ALLO-501 in January 2019. ALLO-501 ALPHA Study Overview. On June 4, 2019, Allogene announced FDA clearance of the IND for ALLO-715. Post-marketing studies to gain additional information. a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), present at several upcoming investor conferences.                 Subscribe media@cellectis.com   		Caitlin Kasunich KCSA Strategic Communications
 TALEN is a registered trademark owned by Cellectis. OUR PIPELINE.                                                                                                                                             Cell lines, Viral Safety for mAb: Prevent, Detect, Remove | 20-May-2020                     { August 5, 2020 – New York – Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on allogeneic gene-edited CAR T-cells (UCART), today announced its results for the three-month and six-month periods ended June 30, 2020. Allogene has exclusive rights to UCART19 in the U.S. while Servier retains exclusive rights for all other countries. The second site, being built in North Carolina, US, is named IMPACT (Innovative Manufacturing Plant for Allogeneic Cellular Therapies) and has an operational go-live target date of 2021. January 15, 2020 – New York (N.Y.) –  Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today the first patient dosing in AMELI-01, the Phase 1 dose escalation clinical trial evaluating a new UCART123 product candidate in relapsed/refractory acute myeloid leukemia (AML).  <br>Asked about which of the candidates are included in the manufacturing agreement with Lonza, a spokesperson for Cellectis told us that "discussions are ongoing"​ about it.                 } View source version on businesswire.com: https://www.businesswire.com/news/home/20191001006159/en/, Lonza   		Dr. Kristin Koehler Investor Relations
 Find out how Cevec Pharmaceuticals... Eppendorf for Bioprocess – Solutions that grow with you | 29-Mar-2019 Identify and understand important and diverse types of therapeutics under development for Cellectis S.A. Identify potential new clients or partners in the target demographic, Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics, Devise corrective measures for pipeline projects by understanding Cellectis S.A.'s pipeline depth and focus of pipeline therapeutics, Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope, Cellectis S.A. - Research and Development Overview, Pipeline Products by Stage of Development, Partnered Products/Combination Treatment Modalities, Pipeline Products - Out-Licensed Products, Out-Licensed Products/Combination Treatment Modalities, Cellectis S.A. - Pipeline Products Glance, Cellectis S.A. - Early Stage Pipeline Products, Preclinical Products/Combination Treatment Modalities, Cellectis S.A. - Pipeline Products by Target, Cellectis S.A. - Pipeline Products by Molecule Type, Cellectis S.A. - Pipeline Products by Mechanism of Action, Cellectis S.A. - Locations And Subsidiaries, Cellectis S.A. - Pipeline by Indication, 2016, Cellectis S.A. - Pipeline by Stage of Development, 2016, Cellectis S.A. - Monotherapy Products in Pipeline, 2016, Cellectis S.A. - Partnered Products in Pipeline, 2016, Cellectis S.A. - Partnered Products/ Combination Treatment Modalities, 2016, Cellectis S.A. - Out-Licensed Products in Pipeline, 2016, Cellectis S.A. - Out-Licensed Products/ Combination Treatment Modalities, 2016, Cellectis S.A. - Pipeline by Target, 2016, Cellectis S.A. - Pipeline by Molecule Type, 2016, Cellectis S.A. - Pipeline Products by Mechanism of Action, 2016, Cellectis S.A. - Dormant Developmental Projects,2016, Cellectis S.A.  - Pipeline by Indication, 2016, Cellectis S.A.  - Out-Licensed Products in Pipeline, 2016, Cellectis S.A.  - Pipeline by Target, 2016, Cellectis S.A.  - Pipeline Products by Mechanism of Action, 2016. André Choulika, Ph.D., Cellectis’ Chairman and CEO, announces that he will focus all his energy on Cellectis’ development activities, and thus, announces his retirement from Calyxt’s Board of Directors, effective immediately.                      | Application Note. It has offices in Paris, France, New York, New York and Raleigh, North Carolina. Therapeutic Programs Under Development. Cancer is a leading cause of death worldwide and is characterized by the uncontrolled growth of abnormal cells whose ability to evade the immune system is key. AMELI-01 replaces the first US clinical trial assessing the UCART123 product candidate. September 1st, 2020 – New York (N.Y.) – Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), will present at several upcoming investor conferences. <br> <br>Startlab c/o Biopôle SA Bâtiment SE-B Route de la Corniche 5 CH-1066 Epalinges. This same technology, developed by Cellectis, could help in designing therapies for many other diseases. <br> <br>                    return vOut; Therapeutic Programs Under Development.                     - Last updated on Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. Our wholly controlled product candidate, UCART123, is a gene-edited T-cell investigational drug that targets CD123, an antigen expressed at the surface of leukemic cells in acute myeloid leukemia (AML). The UCART123 clinical trial in AML, AMELI-01, is a Phase 1, dose escalation study to evaluate the safety, expansion, persistence and clinical activity of  a new UCART123 construct and an optimized production process in patients with relapsed/refractory AML. Title: Cellectis s a product pipeline review 2016, Author: Elmer D. Henry, Name: Cellectis s a product pipeline review 2016, Length: 3 pages, Page: 1, Published: 2016-11-27 Issuu company logo Issuu The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced that it will report its financial results for the second quarter of 2020 together with a business update on Wednesday, August 5, 2020, after the close of the US market. Contact Us; LOCATIONS. ucart19 (all) 2: all0-501 (nhl) 2,3: learn more » all0-501a (nhl) 2,3: learn more » bcma. Calyxt’s Board of Directors has appointed Yves Ribeill, Ph.D., currently a Calyxt Board member, as Chairman, effective immediately. Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual. Under the agreement, Lonza will manufacture Cellectis’ allogeneic, ‘universal’ CAR-T (UCART) product candidates targeting hematological malignancies at the former’s facilities in Geleen, Netherlands. Additionally, Calyxt’s Board of Directors appointed Laurent Arthaud, Cellectis’ Board member, as a Cellectis designated Director, effective immediately.              <br> <br>Lonza is in charge of implementing Cellectis' manufacturing processes as per current Good Manufacturing Practices (cGMP) in a way that meets the highest quality and safety standards outlined by the FDA. This trial, sponsored by Cellectis, is part of an Investigational New Drug (IND) from the US Food and Drug Administration for a new UCART123 construct and an optimized production process, and will evaluate the safety, expansion, persistence and clinical activity of the product candidate in patients with relapsed/refractory AML. By Vassia Barba 03-Oct-2019 - Last updated on 04-Oct-2019 at 15:55 GMT (Image: Getty/bluebay2014) Related tags: Lonza, Cellectis, CAR-T, cell and gene therapy. ALLO-715 is an engineered allogeneic chimeric antigen receptor T (CAR T) cell therapy targeting BCMA, exclusively licensed to Allogene, for the treatment of patients with relapsed/refractory multiple myeloma (MM). Perfusion cell culture processes promise advantages for industrial bioprocessing, like saving space, increasing volumetric productivity, achieving more... Eppendorf for Bioprocess – Solutions that grow with you | 17-Sep-2018 Published on: July 06, 2020, 16:50 E.S.T. Trials designed to examine if the drug or treatment has a clinical activity. <br> <br>Another site is planned to open at Weill Cornell Medicine in New York under the leadership of Dr. Adriana Rossi, Associate Clinical Director, Myeloma Center and Assistant Professor of Medicine, Division of Hematology and Medical Oncology. our allocar t™ pipeline targets a vast array of tumor types. <br> <br>The manufacturing will take place at Lonza's GMP facility in Geleen, Netherlands. Pivotal Phase 7. UCART22 is one of Cellectis’ wholly owned, allogeneic, off-the-shelf gene-edited T-cell product candidates designed for the treatment of relapsed and refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). Phase I - Dose Expansion 6. "Off-the-shelf" immunotherapies The company generated sales of CHF 5.5 billion in 2018 with a CORE EBITDA of CHF 1.5 billion.                     dataLayer.push(dataLayerNews);                         if(i!=(aTags.length-1)) <br>                     } <br>";s:7:"keyword";s:18:"cellectis pipeline";s:5:"links";s:7426:"<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-karla%27s-new-hope-reservations'>Karla's New Hope Reservations</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-yellow-symbiote'>Yellow Symbiote</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-california-congressman'>California Congressman</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-size-of-england-comparison'>Size Of England Comparison</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-william-girling-obe'>William Girling Obe</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-cornerstone-anglicare'>Cornerstone Anglicare</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-ecowas-countries-and-their-presidents'>Ecowas Countries And Their Presidents</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-drive-on-meaning'>Drive On Meaning</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-oecd-most-progressive-tax-system'>Oecd Most Progressive Tax System</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-circa-33-cabernet-sauvignon-2017'>Circa 33 Cabernet Sauvignon 2017</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-weather-sydney'>Weather Sydney</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-summer-french-classes-paris'>Summer French Classes Paris</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-monarch-water-softener-review'>Monarch Water Softener Review</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-the-case-of-the-missing-will-summary'>The Case Of The Missing Will Summary</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-morland-brewery-beers'>Morland Brewery Beers</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-unicef-mexico-statistics'>Unicef Mexico Statistics</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-bloomberg-data-sources'>Bloomberg Data Sources</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-low-calorie-pub-meals'>Low Calorie Pub Meals</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-bumble-dates'>Bumble Dates</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-house-prices-in-ireland'>House Prices In Ireland</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-yulia-putintseva-vs-petra-martic-prediction'>Yulia Putintseva Vs Petra Martic Prediction</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-2003-rugby-world-cup-quarter-final-england-v-wales'>2003 Rugby World Cup Quarter-final England V Wales</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-unicef-salary-scale-2020'>Unicef Salary Scale 2020</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-environmental-challenges-pdf'>Environmental Challenges Pdf</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-van-halen-1984-tour-shirt'>Van Halen 1984 Tour Shirt</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-is-the-use-of-nuclear-weapons-legal%3F'>Is The Use Of Nuclear Weapons Legal?</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-investigator-cover-letter-no-experience-example'>Investigator Cover Letter No Experience Example</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-daniel-boulud-net-worth'>Daniel Boulud Net Worth</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-oecd-model-tax-convention-commentary-2019-pdf'>Oecd Model Tax Convention Commentary 2019 Pdf</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-saudi-arabia-an-ally-or-enemy'>Saudi Arabia An Ally Or Enemy</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-dana-carvey-movies'>Dana Carvey Movies</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-jimmy-page-t-top'>Jimmy Page T-top</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-the-menzingers-rented-world'>The Menzingers Rented World</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-aqua-luna-menu'>Aqua Luna Menu</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-day-drinking-los-angeles'>Day Drinking Los Angeles</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-byo-restaurants-crows-nest'>Byo Restaurants Crows Nest</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-call-your-mother-tv-show'>Call Your Mother Tv Show</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-wedding-venues-under-%24100-per-person-nsw'>Wedding Venues Under $100 Per Person Nsw</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-boathouse-sanford%2C-nc'>Boathouse Sanford, Nc</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-local-harvest-near-me'>Local Harvest Near Me</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-tonga-national-rugby-league-team'>Tonga National Rugby League Team</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-chasin%27-you-writers'>Chasin' You Writers</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-botanist-valentine%27s-day'>Botanist Valentine's Day</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-amphibious-vehicle-definition'>Amphibious Vehicle Definition</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-unchained-movie-israel'>Unchained Movie Israel</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-asi-trainings'>Asi Trainings</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-abattoir-sentence'>Abattoir Sentence</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-katie-smith-writer'>Katie Smith Writer</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-city-of-chester-pa-tax-collector'>City Of Chester Pa Tax Collector</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-pardon-the-interruption-episodes'>Pardon The Interruption Episodes</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-luke-combs-mens-t-shirt'>Luke Combs Mens T-shirt</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-eindhoven-to-rotterdam-flixbus'>Eindhoven To Rotterdam Flixbus</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-thames-water-employee-benefits'>Thames Water Employee Benefits</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-predestined-in-the-bible'>Predestined In The Bible</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-euro-2016-ball'>Euro 2016 Ball</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-unesco-online-volunteering'>Unesco Online Volunteering</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-how-to-start-organic-farming-in-bangalore'>How To Start Organic Farming In Bangalore</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-qatar-history-and-culture'>Qatar History And Culture</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-prezzo-happy-hour-menu'>Prezzo Happy Hour Menu</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-original-casper'>Original Casper</a>,
";s:7:"expired";i:-1;}